Safety and efficacy of MIKE-1 in patients with advanced pancreatic cancer: a study protocol for an open-label phase I/II investigator-initiated clinical trial based on a drug repositioning approach that reprograms the tumour stroma

Peer Review reports

Original Submission
30 Nov 2021	Submitted	Original manuscript
5 Feb 2022	Author responded	Author comments - Yasuyuki Mizutani
Resubmission - Version 2
5 Feb 2022	Submitted	Manuscript version 2
Publishing
8 Feb 2022	Editorially accepted
24 Feb 2022	Article published	10.1186/s12885-022-09272-2

Back to article page